Ovarian cancer: Early relapse

Patricia Pautier; Elsa Kalbacher; Thibault de la Motte Rouge; Franck Bonnetain; Anne Lesoin

doi:10.1016/S0007-4551(17)30160-1

Ovarian cancer: Early relapse

Titre traduit de la contribution: Cancer de l'ovaire: la rechute précoce

Patricia Pautier, Elsa Kalbacher, Thibault de la Motte Rouge, Franck Bonnetain, Anne Lesoin

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

Titre traduit de la contribution	Cancer de l'ovaire: la rechute précoce
langue originale	Anglais
Pages (de - à)	S32-S38
journal	Bulletin du Cancer
Volume	104
Les DOIs	https://doi.org/10.1016/S0007-4551(17)30160-1
état	Publié - 1 mai 2017

Accès au document

10.1016/S0007-4551(17)30160-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{220c93b2afb6401fa9070fedcef070ab,

title = "Ovarian cancer: Early relapse",

abstract = "Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).",

author = "Patricia Pautier and Elsa Kalbacher and {de la Motte Rouge}, Thibault and Franck Bonnetain and Anne Lesoin",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Masson SAS",

year = "2017",

month = may,

day = "1",

doi = "10.1016/S0007-4551(17)30160-1",

language = "English",

volume = "104",

pages = "S32--S38",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Ovarian cancer

T2 - Early relapse

AU - Pautier, Patricia

AU - Kalbacher, Elsa

AU - de la Motte Rouge, Thibault

AU - Bonnetain, Franck

AU - Lesoin, Anne

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

AB - Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

UR - http://www.scopus.com/inward/record.url?scp=85020815589&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(17)30160-1

DO - 10.1016/S0007-4551(17)30160-1

M3 - Article

C2 - 28625313

AN - SCOPUS:85020815589

SN - 0007-4551

VL - 104

SP - S32-S38

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -